May 2026
đź“Ł VC round data is live. Check it out!
Largest Biopharmaceuticals Public Companies in the UK
Benchmark revenue and EBITDA valuation multiples for public comps like
AstraZeneca, GSK, Roivant Sciences, Centessa Pharmaceuticals and Hikma Pharmaceuticals.
 | A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales. | $188 | +30% | $291B | $317B | 5.4x | 16.3x | ||
| In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV. | $26 | +28% | $104B | $125B | 2.8x | 8.2x | ||
| Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. | $30 | +173% | $22B | $17B | 2101.4x | (24.0x) | ||
| Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors. | $40 | +194% | $6B | $6B | 399.5x | (32.7x) | ||
| Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world. | $20 | -31% | $4B | $6B | 1.7x | 6.6x | ||
| MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union. | $9 | +80% | $855M | $871M | 10.7x | (9.7x) | ||
| Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK). | $0 | +28% | $768M | $791M | 10.7x | (24.1x) | ||
| Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea. | $1 | +110% | $485M | $482M | 3164.6x | (20.3x) | ||
| Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States. | $5 | -45% | $318M | ($226M) | (3.1x) | 1.1x | ||
| Animalcare Group PLC is active in the healthcare division in the United Kingdom. It is a generic veterinary medicines company. The company mainly caters to veterinary professionals in the treatment of companion animals through a product line comprised of licensed veterinary medicines and companion animal identification products and services. Its only reportable segment is Pharmaceutical which includes the development and marketing of pharmaceutical products. The company has a presence in Belgium, The Netherlands, Germany, Italy, Portugal, the European Union - Other, Asia, Middle East Africa, Spain, the United Kingdom, and Other Countries of which Spain derives the majority of the revenue to the company. | $4 | +19% | $309M | $325M | 3.2x | 18.0x | ||
| Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans. | $0 | +122% | $308M | $318M | 49.8x | (18.6x) | ||
| Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs. | $3 | -33% | $150M | $80M | 143.6x | (0.9x) | ||
| Agronomics Ltd is an Isle of Man-based investment firm. The company mainly invests in the nascent industry of modern foods, which are environmentally friendly alternatives to the traditional production of meat and plant-based sources of nutrition. | $0 | -- | $98M | $95M | (5.9x) | (2.7x) | ||
| Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group’s main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment. | $0 | +167% | $91M | $110M | 2.2x | (12.8x) | ||
| Eco Animal Health Group PLC is an animal health biotech company. It provides quality products for swine and poultry, anti-infectives to treat illness, improve health, and performance. Its products include Aivlosin/Valosin Solutions and Parasite Solutions. The company’s segments include Corporate/UK, China and Japan, North America, South and Southeast Asia, Latin America, Europe, and the Rest of the World, with the majority of the revenue deriving from China and Japan. | $1 | +60% | $88M | $69M | 0.6x | 7.1x | ||
| OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain. | $2 | -12% | $86M | $82M | - | (11.5x) | ||
| Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). | $0 | -87% | $44M | $3M | 6.2x | (0.1x) | ||
| Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines. | $1 | -36% | $28M | ($27M) | - | 0.4x | ||
| Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction. Geographically, the company derives the majority of its revenue from the United Kingdom and the European Union. | $0 | -93% | $5M | $665K | 0.0x | 0.4x | ||
| Median | $2 | +28% | $309M | $318M | 5.4x | (0.9x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.